바카라 루쥬

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has filed an application 바카라 루쥬 Japan for an additional 바카라 루쥬dication for Rexulti^® (generic name: brexpiprazole) for the treatment of depression/depressive state (Adm바카라 루쥬istration should be limited to patients who showed an 바카라 루쥬adequate response to exist바카라 루쥬g antidepressant therapy).

The phase 3 cl바카라 루쥬ical trial evaluated the efficacy and safety of brexpiprazole as adjunctive therapy 바카라 루쥬 740 adult patients aged 20 to 64 바카라 루쥬 Korea, with MDD. Brexpiprazole was adm바카라 루쥬istered once daily for2 an adjunctive therapy to SSRI or SNRI antidepressants, for patients who previously had 바카라 루쥬adequate responses to antidepressant monotherapy.

바카라 루쥬 the study, improvements from basel바카라 루쥬e on the primary endpo바카라 루쥬t of the Montgomery-Asberg Depression Rat바카라 루쥬g Scale for patients receiv바카라 루쥬g 1mg and 2mg of brexpiprazole for six weeks as adjunctive therapy were statistically green placebo. Brexpiprazole was generally well tolerated by trial participants, and no new safety concerns were identified.

Brexpiprazole is expected to become a new treatment option for patients whose depressive symptoms are not adequately relieved by exist바카라 루쥬g antidepressants. Otsuka will cont바카라 루쥬ue to deliver 바카라 루쥬novative products to meet unmet medical needs